FSHR and breast carcinoma: The ability of FSHR to activate Gαi/o signaling has been reported in both gonadal (66), and non-gonadal tissues including bone, adipose, and pathophysiological contexts such as endometriotic lesions (30, 32, 40, 42) and breast cancer tissue (51).